Deal overview
| Target | ARGO BIOPHARMACEUTICAL CO LTD (CARDIOVASCULAR RIGHTS) |
|---|---|
| Bidder | NOVARTIS AG |
| Price | £50.00 Full version or £25.00 Light version |
| Publication Date | Sep 03, 2025 |
| Abstract | On 3 September 2025, the Chinese clinical-stage biotechnology company Argo Biopharmaceutical Co Ltd ("Argo") announced that it had entered into an additional strategic collaboration with the Swiss pharmaceutical company Novartis AG ("Novartis") for multiple cardiovascular assets in Argo's pipeline. The maximum price payable was US$ 5.36 billion, including upfront payment ... |
| Number of pages (Full version) | 5 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
